Abstract
DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have